Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Gross Margin (2016 - 2025)

Corcept Therapeutics' Gross Margin history spans 10 years, with the latest figure at 98.74% for Q4 2025.

  • For Q4 2025, Gross Margin rose 37.0% year-over-year to 98.74%; the TTM value through Dec 2025 reached 98.3%, down 9.0%, while the annual FY2025 figure was 98.3%, 9.0% down from the prior year.
  • Gross Margin for Q4 2025 was 98.74% at Corcept Therapeutics, up from 97.79% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.74% in Q4 2025 and bottomed at 97.79% in Q3 2025.
  • The 5-year median for Gross Margin is 98.59% (2022), against an average of 98.51%.
  • The largest annual shift saw Gross Margin soared 42bps in 2021 before it plummeted -64bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 98.63% in 2021, then fell by 0bps to 98.56% in 2022, then grew by 0bps to 98.61% in 2023, then dropped by 0bps to 98.37% in 2024, then rose by 0bps to 98.74% in 2025.
  • Per Business Quant, the three most recent readings for CORT's Gross Margin are 98.74% (Q4 2025), 97.79% (Q3 2025), and 98.23% (Q2 2025).